Glaukos Corporation (GKOS)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$1.16 (+0.84%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Glaukos Corporation (GKOS)
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.

Key Insights

Critical company metrics and information
  • Share Price

    $141.29
  • Market Cap

    $7.79 Billion
  • Total Outstanding Shares

    55.14 Million Shares
  • Total Employees

    907
  • Dividend

    No dividend
  • IPO Date

    June 25, 2015
  • SIC Description

    Surgical & Medical Instruments & Apparatus
  • Homepage

    https://www.glaukos.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Financing Activities, Continuing$38.73 Million
Net Cash Flow$-10.64 Million
Net Cash Flow From Investing Activities, Continuing$23.12 Million
Net Cash Flow From Investing Activities$23.12 Million
Net Cash Flow From Operating Activities, Continuing$-72.49 Million
Net Cash Flow From Operating Activities$-72.49 Million
Net Cash Flow, Continuing$-10.64 Million
Net Cash Flow From Financing Activities$38.73 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Other Operating Expenses$153.19 Million
Income/Loss From Continuing Operations After Tax$-149.57 Million
Net Income/Loss Available To Common Stockholders, Basic$-149.57 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Cost Of Revenue$84.28 Million
Gross Profit$276.06 Million
Basic Average Shares$51.95 Million
Basic Earnings Per Share$-2.96
Operating Income/Loss$-132.32 Million
Net Income/Loss Attributable To Parent$-149.57 Million
Income/Loss From Continuing Operations Before Tax$-148.63 Million
Preferred Stock Dividends And Other Adjustments$0.00
Costs And Expenses$508.97 Million
Selling, General, and Administrative Expenses$255.20 Million
Income Tax Expense/Benefit$946,000.00
Operating Expenses$408.39 Million
Benefits Costs and Expenses$508.97 Million
Nonoperating Income/Loss$-16.30 Million
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Diluted Average Shares$51.95 Million
Diluted Earnings Per Share$-2.96
Net Income/Loss$-149.57 Million
Revenues$360.35 Million

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Other Current Assets$337.39 Million
Other Non-current Assets$161.26 Million
Current Liabilities$71.68 Million
Equity$668.51 Million
Liabilities$258.03 Million
Fixed Assets$98.58 Million
Noncurrent Assets$529.26 Million
Equity Attributable To Parent$668.51 Million
Liabilities And Equity$926.54 Million
Accounts Payable$11.10 Million
Noncurrent Liabilities$186.35 Million
Equity Attributable To Noncontrolling Interest$0.00
Intangible Assets$269.42 Million
Inventory$59.90 Million
Assets$926.54 Million
Other Current Liabilities$60.58 Million
Current Assets$397.28 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.